IP Library › Granted Patent US 8,962,666
Granted Patent B2
US 8,962,666 · App. 13/677,071 · Granted Feb 24, 2015

Method for improving cartilage repair and/or preventing cartilage degeneration in a joint

Inventors: Peter Joseph Emans (Maastricht, NL); Lodewijk Willem Van Rhijn (Maastricht, NL); Tim Johannes Maria Welting (Klimmen, NL); Mike De Leeuw (Mheer, NL)
Assignees: Maastricht University; Academic Hospital Maastricht
A61K9/0019A61K9/0024A61K31/42A61K31/728A61L27/52A61L27/54A61K38/2013A61L2300/252A61L2300/414A61L2300/426A61L2300/432A61L2300/452
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,666
App. No.
13/677,071
Granted
Feb 24, 2015
Kind
B2
Abstract

The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.

Claims (8)

1. A method for improving cartilage repair in a joint of a subject in need thereof comprising administering directly into the fat pad of said joint a COX-2 inhibitor in an amount sufficient to effect said improvement.

2. The method according to claim 1 wherein said COX-2 inhibitor is contained in a device suitable for controlled release of said COX-2 inhibitor.

3. The method according to claim 2 wherein said device is a biogel.

4. The method according to claim 3 wherein said biogel comprises a biocompatible polymer.

5. The method according to claim 3 wherein said biogel is biodegradable.

6. The method according to claim 3 wherein said biogel is selected from the group consisting of a hydrogel, a saccharide polymer, microspheres, liposomes, agarose, Carrageenans, Hyaluronan (Hyaff-11), PGA-scaffold, type II collagen-glycosaminoglycan scaffold, glycerol tripalmitate, OPF and gelatine microparticles, PEO-hydrogels with PLGA microspheres, OPF and gelatine microparticles, Collagen/chitosan/glycosaminoglycan with or without chitosan microspheres, P(NiPAAm-co-AAC)/HA hydrogels, collagens, PLA-PEG/IP-CHA and Gelatine/chondroitin/hyaluronate with or without gelatine microparticles.

7. The method according to claim 1 wherein said subject is a human.

8. The method according to claim 1 wherein said joint is a shoulder, elbow, wrist, ankle or hip.

Continuity (3)
Division 12709169 · Feb 19, 2010
Provisional Application 61154328 · Feb 20, 2009
Related Publication 20130123314A1 · May 16, 2013